Latest Articles about PGNX

Salix Beats on Earnings - Analyst Blog

Zacks Equity Research — Tue, 14 May 2013 18:28:01 Z

Salix Pharmaceuticals, Ltd. ( SLXP ) posted first quarter earnings of 56 cents per share, above the Zacks Consensus Estimate of 55 cents and the year-ago earnings of 42 cents. Excluding

Pre-Market Earnings Report for March 15, 2013 : HIBB, BWS, STON, AXAS, ZGNX, CTRN, PGNX, SNMX, JST

NASDAQ.com News — Fri, 15 Mar 2013 00:00:04 Z

The following companies are expected to report earnings prior to market open on 03/15/2013. Visit our Earnings Calendar for a full list of expected earnings releases. Hibbett Sports, Inc. (

Salix Misses on Both Counts - Analyst Blog

Zacks Equity Research — Tue, 05 Mar 2013 19:00:01 Z

Salix Pharmaceuticals, Ltd. ( SLXP ) posted fourth-quarter earnings of 71 cents per share, missing the Zacks Consensus Estimate of 80 cents and well below the year-ago earnings of $1.18.

Weekly CEO Buys Highlight: CVRR, HBAN, VVTV, SXCP, PGNX

GuruFocus — Mon, 28 Jan 2013 00:18:29 Z

According to GuruFocus Insider Data , these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: CVR Refining LP ( CVRR ): CEO and

Mixed Quarter from Salix - Analyst Blog

Zacks Equity Research — Mon, 12 Nov 2012 21:20:01 Z

Salix Pharmaceuticals, Ltd. ( SLXP ) posted third quarter earnings of 95 cents per share, well above the Zacks Consensus Estimate of 64 cents, the year-ago earnings of 77 cents and the

Weekly CEO Buys Highlight: SUSP, ROVI, ZLC, MDW, PGNX

GuruFocus — Mon, 01 Oct 2012 19:49:37 Z

According to GuruFocus Insider Data , these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Susser Petroleum ( SUSP ): CEO

5 Stocks That Dropped the Most Since Gurus Bought Them

Holly LaFon — Thu, 13 Sep 2012 23:33:37 Z

Value investors are primarily interested in the price of a security, though they need to do additional research to determine whether a cheap stock is a good investment. GuruFocus' Guru Bargains

Another Delay for Salix Candidate - Analyst Blog

Zacks Equity Research — Tue, 11 Sep 2012 02:34:42 Z

The US Food and Drug Administration (FDA) recently informed Salix Pharmaceuticals, Ltd. ( SLXP ) that it is still reviewing the company's new drug application (NDA) for crofelemer (125 mg).

Earnings Beat for Salix, EPS View Up - Analyst Blog

Zacks Equity Research — Mon, 13 Aug 2012 18:21:21 Z

Salix Pharmaceuticals, Ltd. ( SLXP ) posted second quarter earnings of 79 cents per share, well above the Zacks Consensus Estimate of 47 cents and the year-ago earnings of 54 cents. Second

Pre-Market Most Active for Jul 30, 2012 : SHAW, S, NOK, BAC, SIRI, FB, ACI, STM, AAPL, QQQ, ZNGA, PGNX

NASDAQ.com News — Mon, 30 Jul 2012 16:39:58 Z

The NASDAQ 100 Pre-Market Indicator is up 3.67 to 2,650.7. The total Pre-Market volume is currently 8,790,062 shares traded. The following are the most active stocks for the pre-market

Positive Data on Theravance Drug - Analyst Blog

Zacks Equity Research — Thu, 12 Jul 2012 02:47:47 Z

Theravance Inc. ( THRX ) recently announced positive top-line results on TD-1211 from a phase IIb study, 0084. TD-1211 is an oral peripherally selective mu-opioid receptor antagonist (PμMA)

Salix Beats; Ups EPS Outlook - Analyst Blog

Zacks Equity Research — Tue, 08 May 2012 19:15:24 Z

Salix Pharmaceuticals, Ltd. ( SLXP ) posted first quarter earnings of 67 cents per share, well above the Zacks Consensus Estimate of 54 cents and the year-ago earnings of 34 cents.

Salix Faces Regulatory Delays - Analyst Blog

Zacks Equity Research — Tue, 08 May 2012 00:00:01 Z

Salix Pharmaceuticals, Ltd. ( SLXP ) is facing a delay where the approval of two of its pipeline candidates is concerned. The company and Progenics Pharmaceuticals ( PGNX )

The Zacks Analyst Blog Highlights: US Airways Group, United Continental Holdings, Delta Airlines, Salix Pharmaceuticals and Progenics Pharmaceuticals - Press Releases

Zacks Equity Research — Tue, 24 Apr 2012 17:30:01 Z

For Immediate Release Chicago, IL - April 24, 2012 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the

Is pullback in the cards for Progenics?

David Russell — Tue, 24 Apr 2012 12:49:05 Z

Progenics Pharmaceuticals is back to a key resistance level, and one investor is bracing for a pullback. optionMONSTER's Depth Charge monitoring program detected the purchase of 1,000 May